Jean F. Voltaire

Array ( [id] => 16572119 [patent_doc_number] => 10894030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells [patent_app_type] => utility [patent_app_number] => 15/703165 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8242 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15703165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717071 [patent_doc_number] => 20170369490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/700351 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15700351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14015105 [patent_doc_number] => 20190069546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => BUFFERED SILVER COMPLEX BIOCIDE [patent_app_type] => utility [patent_app_number] => 15/697765 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15697765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702076 [patent_doc_number] => 20180125858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => BIOAVAILABLE SOLID STATE (17- β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS [patent_app_type] => utility [patent_app_number] => 15/672185 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15672185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117235 [patent_doc_number] => 20180000822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/650459 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 7492 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000185 [patent_doc_number] => 20170304340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOUND OF THE AVERMECTIN FAMILY OR OF THE MILBEMYCIN FAMILY FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS' [patent_app_type] => utility [patent_app_number] => 15/648055 [patent_app_country] => US [patent_app_date] => 2017-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 3929 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15648055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13823767 [patent_doc_number] => 20190015368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => METHOD OF ACNE TREATMENT BY CONCOMITANT TOPICAL ADMINISTRATION OF BENZOYL PEROXIDE AND TRETINOIN [patent_app_type] => utility [patent_app_number] => 15/647331 [patent_app_country] => US [patent_app_date] => 2017-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15647331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699571 [patent_doc_number] => 20170360740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => HISTONE DEACETYLASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/637078 [patent_app_country] => US [patent_app_date] => 2017-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15637078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035649 [patent_doc_number] => 20190328829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => TRIPARTITE COMBINATION THERAPY FOR PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 16/311056 [patent_app_country] => US [patent_app_date] => 2017-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16311056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17250054 [patent_doc_number] => 11185522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Cilastatin for use in the treatment of sepsis [patent_app_type] => utility [patent_app_number] => 16/312825 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 12899 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699545 [patent_doc_number] => 20170360727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LACTATE METAL SALT [patent_app_type] => utility [patent_app_number] => 15/629445 [patent_app_country] => US [patent_app_date] => 2017-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12701932 [patent_doc_number] => 20180125810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => NOVEL ANTITUMORAL USE OF CABAZITAXEL [patent_app_type] => utility [patent_app_number] => 15/627962 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15627962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977458 [patent_doc_number] => 20170281613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'Combination Therapy' [patent_app_type] => utility [patent_app_number] => 15/627238 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 17404 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15627238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13049229 [patent_doc_number] => 10045991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Methods of treating pediatric cancers [patent_app_type] => utility [patent_app_number] => 15/622388 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 34837 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15622388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675499 [patent_doc_number] => 20180116999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHODS OF TREATING FIBROTIC DISEASES USING TETRAHYDROCANNABINOL-11-OIC ACIDS [patent_app_type] => utility [patent_app_number] => 15/619089 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15619089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13746551 [patent_doc_number] => 10166200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Buffered oxygen therapeutics [patent_app_type] => utility [patent_app_number] => 15/617492 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3159 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714131 [patent_doc_number] => 20170368020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => Oral compositions delivering therapeutically effective amounts of cannabinoids [patent_app_type] => utility [patent_app_number] => 15/615521 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963511 [patent_doc_number] => 20170267664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Quinazolin-THF-Amines as PDE1 Inhibitors' [patent_app_type] => utility [patent_app_number] => 15/614104 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13457 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954757 [patent_doc_number] => 20170258908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/600921 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17422 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15600921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15751207 [patent_doc_number] => 10617686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Liquid naloxone spray [patent_app_type] => utility [patent_app_number] => 15/601331 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15457 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15601331 [rel_patent_id] =>[rel_patent_doc_number] =>)